Congress Wants to Ban Monkey Imports. Drug Developers Are Nervous.

The concern isn't hypothetical. When China restricted primate exports in 2020, U.S. imports dropped more than 20%. Research timelines stretched. Costs jumped. A single primate in a toxicology study can cost around $50,000. Scarcity only pushes that number higher.

The Industry Isn't Panicking (Yet)

The reaction from pharma and CROs (contract research organizations, the companies that actually run many of these studies) has been surprisingly measured. That's partly because the regulatory winds were already shifting before this bill dropped.

In April 2025, the FDA announced plans to phase out animal testing requirements for monoclonal antibodies when scientifically appropriate. The NIH has committed over $150 million to scale up what the industry calls New Approach Methodologies, or NAMs.

Charles River Laboratories, one of the largest safety testing CROs in the world, has publicly embraced the shift. Steve Bulera, their Corporate Vice President and Chief Scientific Officer of Discovery and Safety Assessment, predicted that NAMs will "dominate the space, but not overnight." That last part matters.

The Alternatives Are Real (But Not Ready for Everything)

So what replaces a monkey? The toolkit is growing fast:

Organoids are miniature 3D organ models grown from stem cells. They mimic human tissue structure and can test drug toxicity in ways that are actually more relevant to humans than monkey data. Organ-on-chip systems use microfluidic devices with living human cells to simulate how drugs move through liver, lung, or brain tissue. AI and computational models can predict toxicity from massive datasets before a single cell is exposed.

One industry projection estimates these alternatives could save 90% on new drug startup costs by reducing the catastrophic attrition rate (currently, about 90% of drug candidates that pass animal testing still fail in humans).

But validation and standardization remain real obstacles. A February 2026 review from the Association of the British Pharmaceutical Industry found significant gaps between academic innovation and industry-ready tools. Scaling these technologies, making them reproducible, correlating them with existing animal datasets: all of that takes time.

A Familiar Playbook

This isn't Congress's first swing at primate research. The arc follows a pattern. In 2015, the U.S. effectively ended all invasive research on chimpanzees through a combination of endangered species protections and an NIH decision to stop funding chimp studies. The 2000 CHIMP Act had created sanctuaries. The 2007 "Chimp Haven is Home Act" made those retirements permanent.

Each step seemed radical at the time. Each one stuck.

Monkeys are a different story, though. Chimps were used in relatively small numbers for limited applications. Macaques are the workhorse of preclinical testing across oncology, neuroscience, infectious disease, and immunology. Replacing them isn't a single decision; it's a thousand decisions across thousands of drug programs.

The Real Question

The PRIMATE Act hasn't passed yet. It was recently introduced and hasn't even been referred to committee as of early May. But the direction of travel is unmistakable: regulators want fewer primates in testing, Congress is interested in banning imports, and the private sector is investing heavily in alternatives.

The question isn't whether primate testing will decline. It's whether the replacement technologies will mature fast enough to avoid a gap, one where promising drugs sit in regulatory limbo because the old testing methods are banned and the new ones aren't validated.

For biotech companies with programs that depend on primate toxicology data, the smart move is obvious: start building your NAM strategy yesterday. Because whether this bill passes or not, the era of shipping 20,000 monkeys a year across the Pacific is winding down.

UCB Just Dropped $2.2 Billion on a Company That Didn't Exist Two Years Ago

UCB just paid $2.2 billion for Candid Therapeutics, a biotech that launched from stealth barely 18 months ago. The deal reveals big pharma's frenzied bet that T-cell engagers could become the new standard of care for autoimmune diseases.